Laconia recently invested in Brooklyn Health’s $6.5 million seed round, alongside HealthX, Metrodora Ventures, Story Ventures, and RiverPark Ventures.
Brooklyn Health is transforming neuroscience clinical trials through Willis, its electronic clinical outcome assessment (eCOA) platform. Traditional CNS trials rely on subjective clinical interviews to measure treatment efficacy—an approach prone to bias and variability. Willis replaces that with a scalable digital phenotyping solution that brings accuracy and standardization to behavioral measurement.
The Willis platform is composed of:
OpenWillis – a library of validated digital phenotyping methods
WillisPipeline – infrastructure for processing behavioral data
WillisAPI – tools for digital health platforms to adopt proven clinical measures
Brooklyn Health was founded by Anzar Abbas, Founder and CEO. Anzar is a neuroscientist with a career in healthtech. Before starting Brooklyn Health, he served as Director of Digital Health at Cambridge Cognition and held multiple roles at AiCure, including Global Head of Digital Biomarkers and Director of Research and Development. Earlier in his career, Anzar worked as a science communicator for PBS and was an AAAS Mass Media Fellow at HHMI. He holds a PhD in Neuroscience from Emory University and studied History and Philosophy of Science at Michigan State University.
Laconia backs seed-stage B2B software companies bringing structure to complex workflows—and Brooklyn Health’s mission aligns perfectly with that thesis. We’re proud to support Anzar Abbas and the team as they build the future of neuroscience research.
For more information on the investment, read here: https://www.mobihealthnews.com/news/brooklyn-health-scores-65m-improve-mental-health-assessment-clinical-trials